JP Morgan Chase
ACRS icon

JP Morgan Chase’s Aclaris Therapeutics ACRS Stock Holding History

JP Morgan Chase’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18,000
Closed -$146K – 6871
2023
Q1 		$146K Buy
+18,000
New +$228K ﹤0.01% 5252

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

JP Morgan Chase's ACRS Position: Q1 2026 in Review

JP Morgan Chase reduced its Aclaris Therapeutics (ACRS) stake by 22% in Q1 2026, selling an estimated $470K and leaving 486,633 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #4233.

JP Morgan Chase first reported a position in ACRS in Q4 2016 and has held it in 35 quarters since. The position peaked at $7.13M in Q3 2022. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • JP Morgan Chase held 486,633 shares of Aclaris Therapeutics worth $1.7M as of Q1 2026.
  • JP Morgan Chase sold 139,330 Aclaris Therapeutics shares in Q1 2026, an estimated $470K.
  • Aclaris Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4233 holding.
  • JP Morgan Chase first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 35 quarters since.
  • JP Morgan Chase's Aclaris Therapeutics position peaked at $7.13M in Q3 2022.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.